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Hematopoietic progenitor cells are essential source for supportive therapy in high dose 
chemotherapy and for allogeneic stem cell transplantation. Various sources of hematopoietic 
progenitor cells may vary in signal transduction responses. The interrogation of single cell 
signalling networks is a necessary step towards defining mechanisms that promote cancer 
progression, response to therapy and clinical outcome. 
 
The tumor suppressor and transcription factor p53 has also been included in this work to study 
the level of p53 in hematopoietic progenitors. Mutations in p53 are common in a wide range 
of human cancers, but rare in hematopoietic malignancies.  Mutations switch the cellular 
transcription program resulting in deregulation of the stress responses that normally maintain 
cell and tissue integrity. 
 
This study describes the use of flow cytometry for expression of signal transduction in 
different material like bone marrow and leukapheresis products. Samples are collected from 
healthy donors recruited from medical students at Oslo University for bone marrow and 
donors selected by the Bloodbank, Haukeland University hospital for the allogeneic 
leukapheresis products. To be able to describe signal transduction in five different sub 
populations of CD34 positive cells, a panel of antibodies and a protocol for staining of surface 
and intracellular antibodies was established. The flow cytometry protocol was validated by an 
in vitro method; Colony Forming Unit assay and an in vivo xenograft transplantation using 
NSGS mice. The results demonstrate the heterogeneity in the CD34 positive populations also 
other groups has reported. Moreover we found a bimodal peak in the non-stimulated samples 
from the allogeneic leukapheresis products that we don’t find in the healthy bone marrow 
samples that need further investigation. To sum up this work a panel of antibodies has been 
evaluated and a protocol has been established for signaling studies and evaluation of the 









1.1 Hematopoiesis and human hematopoietic stem cells  
Hematopoiesis is the process by which hematopoietic stem cells self-renew, differentiates and 
mature to form the peripheral blood lineages. In the embryo and fetus it takes place in a 
variety of sites including the liver, spleen, thymus, lymph nodes, and bone marrow; from birth 
throughout the rest of life it is mainly in the bone marrow. Bone marrow is a very complex 
organ containing hematopoietic stem cells (HSC) and their descendants, as well as 
mesenchymal stromal and stem cells, osteolineage cells, sinusoidal endothelial cells and 
sympathetic neurons and the extracellular matrix[1]. Bone marrow is also a reservoir for 
several types of adult stem cells; hematopoietic-, mesenchymal- and neural stem cells. 
Normal hematopoiesis is a well-balanced process influenced by its microenvironment 
(stroma) and via cell-cell interactions. Regulation is mediated by intracellular signals of 
specific growth factors, cytokines and other environmental components. Hematopoiesis 
controls the number, self-renewal, proliferation, differentiation, quiescence and localization of 
the HSCs. 
Normal peripheral blood includes mature myeloid cells (erythrocytes, monocytes, 
granulocytes, platelet-producing megacaryocytes and others) and lymphoid cells (B- and T-
lymphocytes, NK- plasma- and dendritic cells and others). All blood cells are derived from 
multipotent hematopoietic stem cells (HSCs) through a succession of progenitors with 
decreasing limited potential of self-renewal under the control of growth factors and specific 
cytokines such as interleukins. HSC’s can give rise to multiple but limited cell lineages unlike 
pluripotent cells that can give rise to many differentiated cells of an organism e.g. embryonic 
stem cells and totipotent stem cells that can give rise to all differentiated cells of an organism 
and extra embryonic tissues such as placenta e.g. fertilized eggs. HSCs normally resides as 
rare cells in the bone marrow in adult mammals together with a hierarchy of progenitors that 
become progressively restricted to several or single lineages. The HSC are usually 
characterized by two properties; 1) Self- renewal which is the ability to give rise to identical 
daughter HSCs without differentiation.  2) The capacity of multilineage differentiation[2]. 
Both these characteristics contribute to maintain the homeostasis of the blood system and 





Figure 1: Hematopoiesis hierarchy 
 
Figure 1: The origin of all blood cell in hematopoietic system is derived from HSCs that contain self-renewal 
capacity and give rise to MultiPotent Progenitors (MPPs) which lose self-renewal potential and start to 
differentiate into all multilineages. MPPs further give rise to common Lymphoid and Myeloid Progenitors, 
CLPs and CMPs. All these oligopotent progenitors differentiate into their restricted lineage commitment: CMPs 
progress to megakaryocyte/erythrocyte progenitors (MEPs) and granulocyte/macrophage progenitors (GMPs), 
CLPs give rise to T cell progenitors and B cell progenitors. Illustration adapted from [3] 
The balance between differentiation and self-renewal of HSCs is organized by symmetric and 
asymmetric cell division [4, 5]. Under normal homeostatic conditions the number of HSCs is 
relatively constant. It is commonly assumed that this balance is achieved by asymmetric cell 
division by generation of two different daughter cells; one daughter cell which maintain the 
stem cell property and one becomes differentiated [5]. It is also assumed that asymmetric cell 
division plays a very important role in cancer disease particularly in connection with the 
“cancer stem cell hypothesis”[6] In some cancers, the transformation of a progenitor cell can 
lead to activation of self-renewal, a property of the “cancer stem cell” Several intrinsic (e.g. 
transcription factors) and micro-environmental(extrinsic) effects plays an important role in 
their maintenance and functional heterogeneity. The extrinsic growth factor/cytokine-
mediated signal leads to a quick transcriptional response (in the order of minutes) and the 
central role of transcription factors in stem- cell biology suggests that alterations in the levels 
of these factors have an essential effect on cell fate. In most cases, the cytokines and growth 
factors that determine differentiation of hematopoietic stem cells into a particular lineage are 
well defined [7]. 
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HSCs are widely used in therapy. Progress in the understanding of the cells of the 
hematopoietic system has provided a keystone in improving clinical hematopoietic cell 
transplants. Hematopoietic stem cell transplants are now routinely used to treat patients with 
cancers and other disorders of the blood and immune systems [8] .  
1.1.1 Identification of HSCs and progenitors 
Estimates have placed the number of HSCs at approximately 1-4 % of nucleated cells in adult 
bone marrow [9] and the limited number make the characterization and isolation challenging 
[10, 11]. The hematopoietic stem cell as a concept was first demonstrated by the two Toronto 
researchers Till and McCulloch [12]. In 1963 Till and McCulloch published their high impact 
paper on hematopoietic stem cells in Nature. Identifying and characterizing properties of 
HSCs began with studies in mice.  
Human HSC’s are functionally defined by their ability to retain the capacity to long term 
repopulate and multilineage differentiation after transplantation in severe combined 
immunodeficiency (SCID) mouse [13] or in the colony-forming assays where HSCs are 
plated at low cell density into semi-solid medium containing appropriate growth factors. 
These assay conditions allow for the proliferation and differentiation of hematopoietic 
progenitors into mature cell types, which can then be enumerated and characterized based on 
their specific morphology. Nonetheless, the hallmark of hematopoietic stem cells is their 
ability to reconstitute lifelong multilineage hematopoiesis in transplanted hosts, like in the 
NOD/SCID mouse [14]. Normal hematopoietic development is a complex biological process 
and in vivo models are required and the observation that immunodeficient mice can serve as 
hosts for human hematopoietic cells represented a major advance. Hematopoietic cells were 
shown to engraft in CB17-Prkdc SCID(severe combined immunodeficient)mice [15]. The 
SCID-hu mouse model for human hematopoietic stem cell engraftment was used to identify 
the Lin-CD34+CD90+ fraction of human bone marrow with repopulating activity [16, 17]. 
Improved engraftment levels were achieved using the NOD (non-obese diabetic) /SCID [18] 
and NOD/SCID/b2mnull mouse strains [19]. Both strains have reduced NK cell activity 
compared with SCID mice and another benefit is polymorphisms in SIRPa that are 
responsible for mediating the enhanced engraftment potential of NOD/SCID mice over SCID 
mice by limiting macrophage phagocytosis of human hematopoietic cells through interactions 
with CD47 [20] 
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A great number of studies based on in vitro cell culture, xenotransplantation of hematopoietic 
stem cells and progenitors in immunodeficient mice and in pre-immune animal fetuses, have 
been carried out to identify the human HSC and uncover the hematopoietic hierarchy.[21] 
To recognize HSC and progenitors from other cells can be a challenge. Morphologically they 
look very much like a lymphocyte and this makes them difficult to identify by morphology 
(size and shape). A heavily used method to identify HSC and progenitors in complex material 
like bone marrow, leukapheresis products, adipose tissue or cord blood is flow cytometry. The 
cells at each maturation stage carry a distinctive set of markers classified by the CD (cluster 
of differentiation) nomenclature and defined by flow cytometry. Researchers rely mainly on 
cell surface proteins, which serve as markers of HSC, progenitors and cells like leukocytes, 
megacaryocytes and erythrocytes. It has been proposed many different cell surface markers 
for HSCs during the years [17, 22-25]. The first cell surface monoclonal antibody used to 
identify human HSCs was CD34, a clone named anti-My-10 mouse monoclonal antibody, 
first called the My10 marker [26]. CD34 has been used in numerous clinical studies over the 
past decade to identify HSCs [17, 27, 28]. Although some studies using xenograft assays 
suggest that, similar to mice, human CD34
–
 HSCs might exist [29, 30] but results among 




1.1.2 Antibodies for detection of HSC subpopulations in mouse and man 
Numerous CD34 mAb have become commercially available, clones like 8G12, 581, 561, 
QBEnd [31]. The CD34 marker is expressed on both immature hematopoietic stem cells able 
to self-renewal and progenitor cells with little or no capability to self-renew. CD34 was 
originally raised against KG-1a, a myeloblastic leukemic cell line [26]. CD34 is used as a 
marker for identification of stem- and progenitor cells in blood and bone marrow and as a 
marker in leukemia diagnosis and subclassification. CD34 is also an important marker in 
clinical transplantations.  
In 1988, in an effort to develop a reliable set of markers to identify these cells, Irving 
Weissman and his collaborators at Stanford University, CA, focused on a set of protein 
markers on the surface of mouse blood cells that were associated with increased likelihood 
that the cell was a long-term HSC. Markers like Thy-1, Sca-1 and negatively selected for T-
cells (CD4 and CD8), B-cells (B220), granulocytes (Gr-1) and monocytes(Mac-1) distinguish 
the mouse long-term (LT-HSC) and short-term (ST-HSC) hematopoietic stem cells (self-
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renew-capable), and the Multipotent progenitors (MPP, low or no self-renew capability — the 
later the developmental stage of MPP, the lesser the self-renewal ability and the more of the 
mature markers) [32]. 
 Four years later Irving Weissman and his collaborators focused on a set of protein markers on 
the surface of leukocytes[33]; Thy-1, known as CD90, CD34 and  a set of Lineage positive 
markers to exclude mature leukocytes. Weissman group and collaborators proposed this set of 
markers to identify human HSCs and they also observed that when these cells begin to 
develop as distinct cell lineages the cell surface markers CD90 and CD34 are no longer 
identified and the positive lineage markers appear. The use of antibodies tagged with 
fluorochromes that selectively adhere to the receptors/antigens on the surface of the cell as a 
tool to identify stem cells is a very old technique named flow cytometry and has the ability to 
fluoresce or emit light energy when activated by an energy source such as a laser beam or 
ultraviolet light, first described by Wolfgang Göhde from the University of Münster, Germany 
in 1968. The combination of the chemical properties of fluorescence and unique receptor 
patterns on cell surfaces or intracellular properties to identify specific populations of stem 
cells makes this method widely used. 
Table 1: Proposed HSC (self-renew capable) cell surface markers for mouse / human material 
like bone marrow, blood, cord blood and leukapheresis products. This markers are the most 
accepted ones in the past decade and has been used in several high impact publications [18, 
23, 24] but there are also other markers and combinations [34, 35] available and it has always 
been a discussion if it is correct to use surface markers to identify undifferentiated HSCs [36] 
Table 1: Antibodies for identification of hematopoietic stem cells and progenitors 
 
*Examples of the markers commonly used 
to isolate human linage negative ( lin−) 
cells are, CD2, CD3, CD4, CD8, CD14, 
CD15, CD16, CD19, CD20, CD56, and 
CD66b and CD235a [40] but this is 
dependent on the experiment performed.  
 













+ A human ortholog is not yet 














1.1.3. Functional assays for detection of human hematopoietic stem cells 
Other not so commonly used indicators for flow cytometry identification of HSCs are 
functional assays like the Aldehyde dehydrogenase (ALDH) and side populations. These are 
functional markers of HSCs unlike the surface markers that characterize the metabolic activity 
of the cell.  ALDH are cytosolic enzymes involved in oxidation of intracellular aldehydes like 
alcohol, and retinol (Vitamin A) [41]  and the activity are shown to be high in the HSC 
population. Side population are another functional marker used to identify HSCs.The protocol 
for identification of side population (SP) cells was originally established for murine bone 
marrow hematopoietic stem cells (HSCs), but it has also been adapted for human HSCs. It has 
been demonstrated that these two functional markers, ALDH and SP identify a heterogeneous 
group of HSC and must be examined further using additional surface markers. The techniques 
demands a lot of adaptions and adjustments for the actual cell type and experiment and there 
are some limitations with these techniques like it depends a lot on a healthy cell population as 
the functionality also reflects the health condition. In this thesis these techniques are not 
included. 
Despite all the effort researchers have put in to develop reliable surface markers or functional 
markers to identify true repopulating human HSC there is still debate on which markers that 
are tied to the unique stem cell function [1, 36, 42].  
 
1.1.4. Clinical use of hematopoietic stem cells  
Hematopoietic stem cell transplants and therapy are routinely used to treat patients with 
cancers and other disorders of the blood and immune systems. Both autologous and allogeneic 
stem-cell transplantations have been important in the progress toward potential cure of 
leukemia, lymphoma, and other malignancies and it has also been a key approach toward the 
cure of some inherited hemoglobinopathy and bone marrow failure conditions. It was in the 
mid 1950´s they realized that bone marrow transplant could be used to treat diseases of the 
marrow and in 1968 the first successful transplant to treat an inherited immunodeficiency 
using a human leukocyte antigen (HLA) matched sibling. In 1975 E. D. Thomas et al 
reviewed the state of HSC bone marrow transplantation, and defined a set of critical issues in 
the field, including HLA matching, infectious complications, graft versus host disease 
(GVDH), etc. and showed clearly that one could use this therapy to cure people with 
leukemia.  Later he reported curing half the leukemia patients who underwent transplantation 
when their disease was in chemotherapy-induced remission [43-45]. E. Donnall Thomas 
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shared the Nobel Prize in 1990 with Joseph E. Murray for the development of bone marrow 
transplantation in treatment of human diseases as leukemia. 
Treatment of leukemia and lymphoma, characterized by abnormal proliferation of leukocytes, 
were among the first clinical use of HSCs. The patient’s own cancerous hematopoietic cells 
are destroyed via radiation or chemotherapy, and then replaced with a bone marrow 
transplant, or with a transplant, leukapheresis product, of HSCs collected from the peripheral 
blood of a matched donor. The transplant is called an allogeneic transplant and a matched 
donor is typically a relative of the patient who has inherited similar human leukocyte antigens 
(HLAs) on the surface of their cells.  It can also be an unrelated person with matched HLAs.  
The heterogeneity of leukemia cells in individual patients has implications for the use and 
development of treatments that specifically affect the products of these gene mutations. This 
heterogeneity in the so-called leukemia stem cells could also complicate the targeting of these 
progenitors with specific antibodies or drugs. 
1.1.4.1. Allogeneic – autologous transplantation 
The two major transplant approaches in use are autologous (using the patient's own 
hematopoietic stem cells) and allogeneic (using related or unrelated donor hematopoietic stem 
cells). Autologous transplant allow the use of high dose chemotherapy with the intent of 
overcoming chemotherapy resistance in tumor cells. This therapy is followed by infusion of 
the patient’s previously stored hematopoietic stem cells. It has also been used to attempt to 
reset the immune system in severe autoimmune disorders [46]. Allogeneic transplant 
approaches to cancer treatment also may involve high-dose therapy, but because of 
immunologic differences between the donor and recipient, complications like GVDH or graft 
failure can occur, other complications like immune effects and infections can occur in both 
autologous and allogeneic transplants. Another use of allogeneic HSCs transplants is in the 
treatment of hereditary blood disorders. Although autologous approaches are associated with 
less short-term mortality, many malignancies are resistant to mega-dose therapy alone and/or 
involve the bone marrow and then require allogeneic approaches for optimal outcome. 
Recently, researchers have observed in animal studies and in vivo studies that hematopoietic 
stem cells appear to be able to form other kinds of cells, such as muscle, blood vessels, and 
bone [47]. If this can be applied to human cells, it may eventually be possible to use 
hematopoietic stem cells to replace a wider array of cells and tissues than once thought.  
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1.2. Signal transduction in hematopoiesis 
Disorders of cell proliferation, differentiation, survival, and migration are fundamental events 
that can give rise to cancer, and abnormalities of signaling through enzyme-linked receptors 
have major roles in this type of disease. 
A cell is highly responsive to specific extrinsic biochemicals such as growth factors, 
cytokines, chemokines and hormones in its environment and it has a pivotal effect on cell 
faith. Bone marrow stromal cells in close proximity to hematopoietic precursors produce 
many of the growth factors and cytokines needed in hematopoiesis. Intracellular signal-
transduction cascades mediate the sensing and processing of a stimulus. The extracellular 
molecules that induce these rapid responses (in minutes and hours) are often not diffusible but 
are instead attached to receptors on the cell surface membrane. Aberrations in these pathways 
are a crucial cause for diseases such as cancer [6]. Cell signaling is dependent on cell surface 
receptors, either gated ion-channel receptors, G-protein coupled receptors or enzyme-linked 
receptors like the Receptor Tyrosine Kinase (RTK).  
1.2.1 Important cytokines, growth factors and receptors in HSC differentiation and 
proliferation 
Cytokines are central in determining lineage fate in the hematopoietic hierarchy by 
controlling proliferation and differentiation. They include interleukins (ILs), colony-
stimulating factors (CSFs), interferons, erythropoietin (EPO) and thrombopoietin (TPO) [30] 
[31]. Hematopoietic cytokines are glycoproteins secreted by fibroblasts, monocytes/ 
macrophages, activated lymphocytes and endothelial cells [48].  
A cytokine is an extracelluar molecule, usually a protein or a steroid hormone produced by 
other cells capable of stimulate growth, proliferation, differentiation and other cellular 
processes. In this process cell signaling is essential. The interaction of cell surface receptor 
extracellular domains with secreted ligands, e.g. cytokines, is essential to most types of cell 
signaling and cell-cell communication. 
In the cell signaling process cytokines are also named ligands. Examples are cytokines that 
are able to bind to specific receptors on the surface of their target cells. The binding activates 
the receptor that in turn activates one or more intracellular signaling pathways. The 
downstream signaling cascade generates responses such as changes in enzyme activity and 
metabolism, gene expression, or ion-channel activity or altered shape and movement of the 
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cell. These cellular responses are able to control cell proliferation, differentiation, maturation, 
and survival.  
It is a considerable overlap in function between many of the growth factors and cytokines and 
these soluble ligands can elicit a wide array of biological responses. Though many of them 
exhibit a functional overlay in their activity their biological actions may differ in subtle but 
important ways, for example cytokines can act on the same cell type to mediate similar 
effects. Both the redundancy and the definite differences can be explained by the sharing of 
common receptor subunits in combination with their own specific receptors [31] 
Growth factors and cytokines are essential in regulating self-renewal, survival, proliferation, 
differentiation and function of hematopoietic cells and particularly G-CSF and IL-3 are key 
regulators of myeloid differentiation. [32] IL-3 is also referred to as multi-lineage colony 
stimulating factor and is produced by T cells and monocytes [30, 33]. IL-3 is not essential for 
the maintenance of normal hematopoietic steady-state functions [37] but are important for 
emergency hematopoiesis and immune response. IL-3 is usually produced in response to 
infections and injury, and serves to increase leukocyte numbers and enhance their state of 
activation [36]. G-CSF is produced by monocytes, fibroblasts and endothelial cells and is the 
major cytokine regulator of neutrophilic granulocytes [38]. G-CSF is used clinically to treat 
myelosuppression and its resulting immunodeficiency, as well as to mobilize hematopoietic 
stem cells and – progenitors from the bone marrow to peripheral blood, facilitating 
leukapheresis collection for transplantation [38]. 
 1.2.2 Cell membrane bound receptors 
Growth factors and cytokines usually require enzyme-linked receptors like the Receptor 
Tyrosine Kinases (RTK) or cytokine receptors and can mediate a direct and rapid effect. 
Multiple cytokines and growth factors utilizes common receptor subunits and common 
intracellular signaling pathways This shared use of signal transducers in the multichain 
cytokine receptor complexes can explain the functional redundancy of cytokines [56]. The 
membrane bound receptors contain an extracellular binding domain and an intracellular signal 
transduction domain. The intracellular domain has either intrinsic enzyme activity or will 
interact with a directly associated enzyme. The activation process of cytokine receptors is 
similar to members of the tyrosine kinase receptor family [33, 47, 48]. The family harbors 
tyrosine kinase domains that catalyze the transfer of phosphate groups to activate downstream 
signaling pathways. These receptors also allow protein-protein interactions via other structural 
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motifs like the SH2 and SH3 domains. The non-receptor tyrosine kinase members recruit 
intracellular tyrosine kinases to activate their signaling pathway 
Kinase enzymes that specifically phosphorylate tyrosine amino acids are termed tyrosine 
kinases. The largest family of tyrosine kinases is the Src family [49]. They are all 
characterized by containing intracellular Src Homology 2 and -3 (SH2 and SH3) domains, 
held there partly by their interaction with transmembrane receptor proteins and partly by 
covalently attached lipid chains [49]. Another tyrosine kinase is Phosphoinositide 3-kinase 
(PI3 kinase) which phosphorylates lipids rather than proteins which serve as docking sites for 
signaling proteins [57].  
Cytokine-type receptors are much like receptor tyrosine kinases, except they lack kinase 
activity themselves. They function by binding a non-receptor tyrosine kinase, thereby doing 
the same job with two separate proteins. The close association with non-receptor tyrosine 
kinases that transduce cytokine-mediated signals creates the functional equivalent of a 
receptor tyrosine kinase.    
The cytokine receptor family is transmembrane receptors expressed on the cell surface. They 
are characterized by their lack of intrinsic tyrosine kinase activity and they are by the basis of 
common structural features grouped into six major families: Class I cytokine receptors, class 
II cytokine receptors, TNF receptors, IL-1 receptors, tyrosine kinase receptors, and chemokine 
receptors. The class I cytokine receptors, also known as the hematopoietin receptors, are the 
largest group among the cytokine receptor family. Most cytokine receptors share subunits, 
e.g. receptor for GM-CSF and IL-3 share subunit βc and Thrombopoietin (TPO) and G-CSF 
share a single chain subunit. The shared subunit is the signal transducing subunit and the 
structure is similar to other members of the cytokine receptor family. It both receives signals 
initiated by cytokine binding and is responsible for broadcasting signals to downstream 
signaling proteins [50] 
1.3.3.Ras-MAP kinase pathway 
One of the most common intracellular signaling pathways triggered by RTKs is the Ras-
Mitogen Activated Protein (MAP) kinase cascade and it is a key signaling pathway involved 
in regulation of cell proliferation, differentiation and survival by the transmission of signals 
from membrane bound receptors. The Ras-MAP kinase signal transduction pathway consist of 
a kinase cascade that is regulated by phosphorylation and dephosphorylation by specific 
kinases, phosphatases, GTP/GDP exchange proteins, adaptor proteins and scaffold proteins. 
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The downstream cascade of enzymes terminates in the production of transcription factors 
[51]. Irregular signaling contributes to cancer and other human diseases and constitutive 
activation of MAP kinase proteins in experimental models has been shown to cause cell 
transformation and is implicated in tumorigenesis [52]. The Ras-MAP kinase pathway is often 
involved in sensitivity and resistance to leukemia therapy [52] and is estimated to be mutated 
in 30% of all cancers [53].  
The Ras-MAP kinase pathway can be activated by growth factors which will phosphorylate 
the membrane-associated SH2 domain on the cell membrane receptor making it a docking site 
for the Guanine TriphosPhate (GTP)/Guanine DiphosPhate (GDP) exchange factor SOS 
(named after the Drosophila homolog protein Son Of Sevenless). This activates Ras, a 
monomeric GTPase localized and anchored at the plasma membrane. In normal quiescent 
cells Ras is GDP bound and inactive [54].  Ras function as a molecular switch and SOS 
converts Ras-GDP to Ras-GTP, and this in turn activates a range of downstream effector 
targets, of which Raf, a MAP kinase kinase kinase is the best characterized.  Ras are activated 
by the majority of growth factor receptors and bind and recruit Raf to the cell membrane upon 
activation. Ras activates the first serine-threonine kinase in the MAP kinase cascade. Each of 
the three kinases in this cascade then activates the next by phosphorylating it. Because all 
three kinases in this pathway phosphorylate multiple substrates, the initial signal is amplified 
at each step. Each member of the Ras-Raf-MEK–Erk cascade has multiple isoforms with 
important biological consequences. If preferred isoforms are paired the most optimal 
amplification and transduction will find place [53].  
 
Figure 2: The Ras-MAP kinase pathway 
Activated ERK has many substrates in 
the cytosol [e.g.cytoskeletal proteins, 
phospholipase A2, and signalling 
proteins including tyrosine kinase 
receptors, SOS, signal transducer and 
activator of transcription proteins 
(STATs) and others. 
 
ERK can also enter the nucleus to 
control gene expression by 
phosphorylating transcription factors 
such as Elk-1 and other Ets-family 
proteins. Grb2, growth-factor-receptor-
binding protein 2; SOS and SRF-serum 






The three serine/threonine kinases are a MAP kinase kinase kinase (MAPKKK) like Rapidly 
Accelerated Fibrosarcoma (Raf), a MAP kinase kinase, like MEK and MAP kinase (MAPK) 
like Extra cellular signal Regulated Kinase (Erk1/2). There are four well-known MAPKs, the 
Erk 1/2, the c-Jun amino terminal kinases (JNK12/3), p38 kinases and Erk5. Generally, the 
Erk1/2 part of the pathway is activated by growth factors and cytokine ligands, whereas the 
JNK, p38 and Erk5 cascades are activated by inflammatory cytokines and different kinds of 
cell stress, like heat shock osmotic stress and ionizing radiation. The Raf kinase is required for 
phosphorylation of the MAP kinase kinase Mitogen associated /Extracellular regulated 
kinase-1 (MEK1).  The MAP kinase Erk1/2 is the only known target for MEK1/2 
phosphorylation [49]. Activated Erk1 and Erk2 has a variety of substrates and the number of  
Erk1/2 targets are high (> 60) [50]. Erk1/2 are also able to translocate to the nucleus and 
phosphorylate additional transcription factors, such as Elk-1, cAMP response element binding 
protein, Fos and globin transcription factor 1 and others [50]. Erk can also apply negative 
feedback by interfering with Ras activation by phosphorylation of SOS or Erk can 
phosphorylate Raf and MEK. This will alter the stability and activation of the signaling 
cascade [50].  Additionally certain protein phosphorylation events will serve to shut down or 
slow down the pathway which is a very intricate process involving fine tuning signaling 
originating from a growth factor or a mitogen [51]. 
 
1.4. JAK/STAT pathway 
The JAK/STAT pathway is a main pathway for a wide array of cytokines and growth factors. 
The pathway is essential to hematopoiesis, immune development, mammary gland 
development and lactation, adipogenesis and other important cellular processes.  The large 
family of cytokine receptors includes receptors for many kinds of local mediators and they are 
often associated with the family of cytoplasmic tyrosine kinases, Janus kinases (JAKs). JAKs 
appears to be a pivotal mediator of diverse cytokine signaling pathways [52, 53] [54].The 
JAK kinases are essential for phosphorylation of cytokine receptors, which results in 
establishment of docking sites on the receptors for such as STATs, Src-kinases and other 
signaling intermediates. The STATs are referred to as transcription factors or latent gene 
regulatory proteins because they only migrate into the nucleus and regulate gene transcription 
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after they have been activated. These transcription factors were originally described by 
Darnell and his colleagues [55]. 
Figure 3:  Signaling via the JAK-STAT pathway. 
 
 
The recruitment of the JAK kinases appears to result in phosphorylation either by auto-
phosphorylation or cross-phosphorylation by other JAK kinases or other tyrosine kinase 
family members. The increased JAK kinase activity will result in phosphorylation of tyrosine 
sites on the receptors and the receptors can then serve as docking sites that allow binding of 
other SH2-domain containing signaling molecules such as STATs, Src kinases, protein 
phosphatases and other adaptor signaling molecules. Some adaptor proteins can also bind to 
sites and couple cytokine receptors to the Ras-MAP-kinase signaling pathway. STATs contain 
a SH2 domain and a tyrosine residue that plays an important part in STAT activation [56]. 
Phosphorylation of the tyrosine residue is essential for the STATs dissociation and 
dimerization via their SH2 domain. The phosphorylation of STATs is known to occur 
immediately after the binding of a cytokine or growth factor to their receptors [56]. Activated 
STAT dimers translocate and accumulate in the nucleus where it activates transcription of 
target genes. The STAT family consists of 7 members, STAT 1-6. STAT5a and STAT5b are 
encoded by two separate genes.  An important issue with STAT3 is its association with 
cancer. Constitutively activated STAT3 has been identified in many types of cancer, like head 
and neck, mammary, multiple myelomas and other hematopoietic [57]. 
 
 Figure 3. Ligand binding induces a 
conformational change of the cytokine receptor 
and allows phosphorylation of JAK proteins. 
Activated JAKs phosphorylate tyrosine residues 
in the receptor cytoplasmic domain and provide 
docking site for STAT proteins. Phosphorylated 
STATs dissociate from the receptor, dimerize 
and translocate to the nucleus where they 
modulate gene expression. 
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1.5. p53 – The guardian of the genome. 
p53 is one of the most important tumor suppressor proteins, containing transcriptional 
activation, DNA binding, and oligomerization domains encoded by TP53. The encoded 
protein is normally “off” but responds to diverse cellular stresses to regulate expression of a 
wide variety of target genes, thereby inducing cell cycle arrest, apoptosis, senescence, DNA 
repair, or changes in metabolism and with this p53 play a critical role in maintenance of “cell 
integrity” under stress conditions. p53 is the most frequently inactivated tumor suppressor 
gene in human cancer and clinical studies have shown that p53 deletions or mutations are 
present in approximately 50% of human cancers. It was first believed to be an oncogene when 
first described in 1979 but convincing genetic and functional studies has revealed the 
characteristic properties of p53 [58]. A very descriptive example is the Li Fraumeni 
syndrome, where a genetic defect in p53 leads to a high frequency of cancer in affected 
persons. 
 Upon DNA damage, the sensor protein ataxia-telangiectasia mutated (ATM) is activated, 
which phosphorylates various downstream target proteins and induces the cell cycle 
checkpoint response. The general function of cell cycle checkpoint response is to detect 
damaged or abnormally structured DNA and to coordinate cell cycle progression with DNA 
repair. Their function is to slow or arrest cell cycle progression, thereby allowing time for 
appropriate repair mechanisms to correct genetic lesions before they are passed on to the next 
generation of daughter cells. 
The best understood activity of p53, a common activation pathway and one of the first effects 
of p53 expression is after sensing DNA damage, activated ATM directly phosphorylates the 
tumor suppressor p53 at serine 15 within its amino-terminal transactivation domain. ATM 
also activates CHK2, a serine threonine kinase, which phosphorylates p53 at threonine 18 and 
serine 20 [59]. ATM also phosphorylates MDM2, an ubiquitin ligase that targets p53. These 
phosphorylations modify p53 and MDM2 and leads to transcriptional activation and 
stabilization of p53 [60]. p53 stimulates the expression of p21, an inhibitor of cyclin-
dependent kinases (CDKs). CDKs are a family of protein kinases that are involved in the cell 
cycle as regulators and transcription regulation. CDKs and cyclin proteins are major control 
switches causing the cell to move from G1 phase to S or from M to G2. Activation of p21 will 
induce a delay or an arrest of the cell cycle to repair the DNA damage if it’s repairable. If the 
DNA damage is too high or irreparable p53 will induce transcription of proapoptotic genes 
such as BAX, NOXA and PUMA to induce cell death [61, 62]. 
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The importance of HSC´s for various transplantation therapies of incurable diseases such as 
leukemia’s is obvious and continuous efforts to elucidate the precise functions of p53 as a 
main regulator of HSCs will remain crucial and provide an insight into new strategies for 


































Hematopoietic progenitors have their malignant couterparts in myeloproliferative disease, 
myelodysplasias and various leukemias. Jak/STAT and MAPK/Erk pathways appear 
frequently involved in malignant hematopoieses [63] It is therefore of great interest to 
determine the signaling in normal hematopoiesis for comparison of rare or more more 
frequent malignant clones in bone marrow malignancies. The main aims of this thesis have 
been to develop a panel of antibodies for multiparametric characterization of signal 
transduction in the Jak/Stat and MAPK/Erk pathways and p53 in healthy hematopoietic stem 
cell- and myeloid progenitor populations. The multiparametric characterization of signal 
transduction was tested on different sources of hematopoietic progenitors, such as healthy 
bone marrow and leukapheresis products from donors for allogeneic stem cell transplantation.  
 
The objectives have been: 
 
1) Establish a protocol and a panel of antibodies with a set of surface markers and 
intracellular markers to define five different hematopoietic stem cell and myeloid 
progenitor populations and characterize cytokine response and signaling patterns in 
these populations in healthy individuals. 
 
2) Establish a FACS sorting protocol for sorting of bone marrow derived mononuclear 
cell leukapheresis products . 
 
 
3) For validation of stemness puroposes only: Examine the correlation between the 
different hematopoietic stem- and myeloid progenitor populations with ex vivo assay 
Colony Forming Unit (MethoCult) and in vivo xenotransplantation. To do/future 













3. Materials and Method 
 
3.1  Cell lines and primary cells from healthy donors 
The suspension wild-type TP53 MOLM-13 AML cell line , the promonocytic U937 
suspension cell line and the suspension AML myeloblast cell line KG1a was obtained from 
ATCC (American Type Culture Collection, Manassas, VA, USA). MOLM-13 and U937 was 
cultured in Roswell Park Memorial Institute (RPMI)-1640 medium (Sigma-Aldrich, Inc., St. 
Louis, MO, USA). KG1a was cultured in Dulbecco’s Modified Eagle Medium (Sigma-
Aldrich). Cell culture media were supplemented with 10% heat-inactivated Fetal Bovine 
Serum (FBS) (PAA Laboratories GmbH, Pashing, Germany), 50 UI/mL Penicillin – 50 
μg/mL Streptomycin and 2 mM L-glutamine (all from Sigma-Aldrich). The cells were kept in 
humidified incubators at 37°C with 5% CO2 and observed under bright field microscope 
daily. Cell lines were maintained at 0.2-1.0×10
6
 cells/mL for the duration of the experiment 
and split at a ratio of 1:5 three times a week. 
Donors for allogeneic hematopoietic stem cell transplantation were voluntary recruited for 
donation of leukocytes (ethical approval, REK Vest, University of Bergen). Healthy 
individuals were recruited for donation of bone marrow by aspiration from puncture of 
posterior crista (ethical approval REK Sør-Øst, University of Oslo). Bone marrow from 
healthy donors were cryopreserved, stored and thawed according to procedures described 
below and in previous publications [ref].  
 
3.1.1 Thawing of bone marrow mononuclear cells 
Cells were thawed rapid in hands until almost defrosted. 1 mL of FBS was added dropwise 
and the vial was left at room temperature (RT) for 5 minutes. The cell suspension was then 
slowly transferred to a tube containing RPMI with 10% FBS and 80 units/mL[64] DNase 
(deoxyribonuclease I from bovine pancreas) (Sigma-Aldrich, St. Louis, cat. no. 2025), 
carefully mixed and incubated in RT for 10 minutes. The tube was centrifuged at 300G x 7 
minutes, supernatant was removed and RPMI with 2 % FBS was added. Volume was adjusted 
according to the number of cytokines and timepoints in the stimulation assay. Cell suspension 
was carefully mixed and left in the cooling room (5-7°C) for 1 hour and 30 minutes before 








3.1.2. Cell line cryopreserving 
Cells were counted and followed by centrifugation at 500g × 5 min. The supernatant was 
discarded and the pellet was dissolved in freezing medium (70% medium, 20% FBS and 10% 
DMSO at a concentration of 10.0x10
6 
cells/mL. 1 mL of the well mixed cell suspension was 
transferred to a cryogenic vial (Sarstedt, Nümbrecht, Germany). The vials were stored at -
80C for 24 to 72 hours before transferring to a liquid nitrogen tank (-196C) for long term 
storage. 
Cells were counted by using a hemocytometer. All cell work was carried out under sterile 
conditions through the utilization of a laminar flow bench with a high efficiency particulate 
air (HEPA) filter. 
3.1.3. Cell line thawing 
Cells were rapidly thawed by heating the vial containing approximately 5.0×10
6
 
cryopreserved cells in hands until it was almost defrosted. 1 mL of medium was added 
dropwise, and the vial was left at room temperature (RT) for 5 minutes. The cell suspension 
was then transferred to a 25 cm
2 
cell culture flask containing 9 mL of medium. After one day 
culturing the cell suspension was transferred to a 15 mL tube and centrifuged at 500g × 5 min. 
The supernatant was discarded to remove the cryoprotectant dimethyl sulfoxide (DMSO, 
Scahrlab S.L., Sentmenat, Spain), and the pellet was resuspended in 10 mL of fresh medium 
in the cell culture flask. The cells were cultured under normal growth conditions. 
 
3.2. Flow cytometry 
3.2.1 Antibody panel 
Antibody panel for human bone marrow and leukapheresis product analyzed are presented. 
Flow cytometric analysis was performed in the UiB core facility for flow cytometry with 
instruments BD Fortessa and BD Aria Fortessa (both Becton Dickinson, La Jolla, CA, US) . 
The optimal concentrations for each antibody, empirically determined in pilot studies are 












* FITC 22-7778/eBioscience 









CD34 8G12 PerCPCy5.5 347222/BD Biosciences 7 l 
CD38 HB7 Brilliant Violet 605 562665/BD Biosciences 5 l 
CD90 5E10 PECy7 561558/BD Biosciences 3 l 
CD123 9F5 Brilliant Violet 421 562517/BD Biosciences 5 l 
CD45RA HI100 Brilliant Violet 510 304142 / BioLegend (San 
Diego, CA, US) 
5 l 
p53 DO-7 PE 556534/BD Biosciences 15 l 
Erk1/2 (P-p44/42 
MAPK) 





PE 612569/BD Biosciences 15l  
Stat5 pY694; 47 Alexa Fluor 647 612599/BD Biosciences 20l  
 
 
The Lin- antibody purchased from eBioscience contains markers for mature leukocytes and 
erythrocytes and contains CD2, CD3, CD14, CD16, CD19, CD56, CD235a  
 
PARP (poly-ADP ribose polymerase) antibody is included as a live/dead cell marker for fixed 
cells. PARP is a DNA repair enzyme that is activated by DNA strand breaks and a target of 
the caspase protease activity associated with apoptosis. Proteolytic cleavage of PARP by 
caspase 3 into 24- and 89-kDa fragments inactivates the PARP enzyme and results in epitope 
unmasking for the anti-PARP clone F21-852. It has been proposed that inactivation of PARP 
directs DNA-damaged cells to undergo apoptosis rather than necrotic degradation, and the 
presence of the 89kDa PARP cleavage fraction is considered to be a marker of apoptosis. 
CD34: Cells expressing CD34 are normally found in the umbilical cord and bone marrow, but 
is also expressed by small vessel endothelial cells. CD34 is a glycosylated transmembrane 
protein related to the proteins podocalyxin and endoglycan, and represents a well-known 
marker for primitive blood- and bone marrow-derived progenitor cells especially for 
hematopoietic and endothelial stem cells. The CD34 gene contain possible binding motifs for 
MYB, MYC, and ETS [65] transcription factors involved in cellular differentiation and fate 
determination [66, 67] . Even if CD34 is shown to be involved in homing of progenitor cells, 
its function mainly remain elusive.  
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CD38: Cyclic ADP ribose hydrolase (CD38) is a glycoprotein found on the surface of many 
immune cells. In humans, it is expressed on T cells, B cells, NK, myeloid, plasma, and 
dendritic cells. By functioning as both a cyclase and a hydrolase, CD38 mediates lymphocyte 
activation, adhesion, and the metabolism of cADPR and NAADP both of which are second 
messengers. The CD34+CD38- population of hematopoietic stem cells is thought to define 
the most multipotent cells (HSC) 
CD90: Thy-1 is a glycophosphatidylinositol (GPI) anchored conserved cell surface protein. 
Thy-1 can be used as a marker for a variety of stem cells. Thy-1 is expressed on endothelial 
cells, smooth muscle cells, a subset of CD34+ bone marrow cells, and umbilical cord blood-, 
cardiac fibroblasts, and fetal liver-derived hematopoietic cells. It is considered a major marker 
of HSC together with CD34. In human HSCs, Thy-1 cells are all CD34 positive.  
CD123: CD123 is also known as IL-3 receptor α-chain and is the primary low-affinity subunit 
of the IL-3 receptor. CD123 is expressed by low levels on monocytes, eosinophilic 
granulocytes, myeloid dendritic cells, and subsets of hematopoietic progenitor cells. 
CD45RA: CD45RA is an exon 4 splice variant of the tyrosine phosphatase CD45. The 
isoform is expressed on resting/naive T cells, medullary thymocytes, B cells and monocytes. 
p53: Antibody clone DO-7 reacts with the wild type and mutant type of the tumor suppressor 
p53 protein and recognizes an epitope between amino acids 1-45 of all known forms of the 
human p53 molecule. 
Stat3: Signal transducer and activator of transcription (Stat) 3 is a 92-kDa protein that is 
phosphorylated in response to cytokine and growth factor stimulation, responding to 
phosphorylation with cytoplasmic-nuclear shuttling and thereby acting as a transcription 
factor.  The anti-Stat3 clone used in this study detects only phosphorylations of Tyr705, 
Stat5: The Stat5 phospho-Tyr694 antibody recognizes the regulatory tyrosine 
phosphorylation of human Stat5 protein 
 
3.2.2. Protocol for stimulation with cytokines and staining for flow cytometry. 
Stimuli used in the project were G-CS and IL-3 (final concentration 20 g/mL), both 
purchased from ProSpec Tany TechnoGene Ltd, Israel. The cytokines were frozen in aliquots 
in a -80C freezer.  
 
Density gradient centrifugation isolated  mononuclear cells from healthy bone marrow donors 
(kind gift from Dr. June Myklebust, Radiumhospitalet) were thawed as previously described 
and rested one hour and 30 minutes in RPMI medium with 2% FBS in the cooling room (5-
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7°C). Leukapheresis left-over cells received from the Bloodbank, HUS was resuspended in 
RPMI with 2% FBS and rested for one hour and 30 minutes in in the cooling room (5-7°C). 
Cytokines were added to cells in separate 15 mL tubes (Sarstedt, Germany) and for two time 
point measurements, 5 and 15 minutes. The suspension was mixed well and placed in a water 
bath at +37C for 5 or 15 minutes. Signal transduction was halted by fixing the cells with a 
final concentration of 1.6% paraformaldehyde (PFA) diluted from 16% PFA (Alfa Aesar 
GmbH, Germany) for 15 minutes at room temperature. Cells were washed once and 
supernatant was removed. Cells were resuspended in PBS and Octagam (Octapharma AG, 
Switzerland) to a final concentration of 50 ug/mL was added to prevent nonspecific binding 
of antibodies and were incubated for 10 minutes in room temperature. Cells were centrifuged 
and washed once and resuspended in staining buffer (1xPBS with 0.5% BSA) and then 
stained with pre-determined saturating concentrations of fluorochrome-conjugated surface 
markers, 30 minutes in the dark in room temperature. After two washing steps the supernatant 
was removed and the cells were permeabilized with ice-cold 100 % MetOH (Sigma Aldrich) 
for 30 minutes at +4 C. Cells were washed twice to remove remaining MetOH and 
resuspended in staining buffer and stained with pre-determined saturating concentrations 
intracellular signaling antibodies for 30 minutes. After 2x wash in staining buffer the cells 
were resuspended in staining buffer. 
 
 
Figure 4. Experimental outline for detection of intracellular signaling events in single cell 




Antibody expression levels were quantified using the BD LSR equipped with four lasers (488 
nm-50mW, 561nm-50mW, 640nm-70mW and 405nm-40mW) and 15 fluorescence detectors. 
Cytometer Setup & Tracking (CST) quality control was performed on the flow cytometer 
each day during analysis period. Fluorescence data was compensated at the time of 
acquisition using a compensation matrix set up using BD FACSDiva acquisition software 
(BD Biosciences). The compensation controls are BD Comp beads Anti-mouse Ig, κ (Cat no 
552843, BD Biosciences) single stained with all the antibodies in the panel and a tube with 
unstained cells. FCS 3.0 data files were then uploaded to FlowJo (Tree Star,Ashland,OR,US) 
for further analysis and gating out of debris, non- viable cells and doublets. Non-viable cells 
and doublets were excluded based on PARP staining (viability staining) and forward scatter 
height versus area plots, respectively. Surface- and intracellular marker expression levels were 
calculated by subtracting the median fluorescence intensity (MFI) of non-stimulated cells 
from the MFI of cells stimulated with cytokines. 
 
3.2.2.1. Compensation controls: 
To account for spectral overlap between fluorochromes, anti-mouse Ig, κ particles, which bind 
any mouse κ light chain-bearing immunoglobulin, and negative control BD CompBeads (BD 
Biosciences), which have zero binding capacity, were used to set compensation levels. To 
prepare CompBeads for collection, one drop of anti-mouse Ig, κ and one drop of negative BD 
CompBeads, 100 μl of staining buffer and identical μl of fluorochrome-conjugated antibody 
as for the sample were added to a 5 mL FACS tube and incubated at RT for 30 minutes. After 
incubation, beads were then washed in 3 ml FACS buffer and centrifuged at 400 G for 10 
minutes. The supernatant was aspirated and beads were resuspended in 300 μl FACS buffer 
for acquisition. 5000 events were acquired on the LSR Fortessa flow cytometer, while gating 
on positive and negative populations for compensation matrix and automatic compensation 












3.3. Fluorescent Activated Cells Sorting (FACS) for xenotransplantation and Colony 
forming unit assay. 
Leukapheresis left-over product received from the Bloodbank, HUS was resuspended in 
staining buffer (1xPBS with 0.5% BSA) in room temperature under sterile conditions and cell 
number was determined using a hemocytometer. After treating the cells with Octagam 
(Octapharma AG, Switzerland) to a final concentration of 50 g/mL for preventing non-
specific binding of the antibodies, the single cell suspension was stained in 15 mL tubes with 
identical pre-determined saturating concentrations surface markers as for the intracellular 
signaling assay.  








Figure 5: The sample in a single cell 
suspension will pass by the laser 
interrogation point one by one due to the 
hydrodynamic focusing and pressure. The 
central core were the sample is injected are 
enclosed by an outer sheath that contains 
faster flowing fluid caused by different 
pressure. 
The fluorescent signal from the cells will 
pass by filters of a set range of nanometers 
and the filtered fluorescent signal will be 
detected by Photo Multiplier Tubes 
(PMT). The signal will be amplified, 
converted and transmitted to the computer. 
The data are stored in a Flow Cytometry 
Standard (FCS) format. 
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For 500 L sample the following amounts were used: 
Lin- FITC    50 L 
CD34 PerCPCy5.5   35 L 
CD38 Brilliant Violet 605  30 L 
CD90 PECy7    15 L 
CD123 Brilliant Violet 421  25 L 
CD45RA Brilliant Violet 510 25 L 
 
The cells were incubated with the antibodies in room temperature for 30 minutes in the dark. 
After 2 x wash and centrifugation at 350 G in 10 minutes to get rid of unbound antibodies the 
cells were resuspended in staining buffer. Cell sorting on a BD FACS Aria SORP II  
configured with four lasers (488nm-100 mW, 532 nm-150mW, 640 nm-40 mW and 405 nm-
50 mW) and 15 fluorescence detectors was performed on the four following populations:  
 
Hematopoietic Stem Cells: HSC - CD34+CD38-CD90+CD123-CD45RA- (Lin-) 
Multipotent Progenitor: MPP - CD34+CD38-CD90-CD123-CD45RA (Lin-) 
Common Myeloid Progenitor: CMP - CD34+CD38+CD90-CD123+CD45RA- (Lin-) 
Granulocyte-Macrophage Progenitor: GMP - CD34+CD38+CD90-CD123+CD45RA+ (Lin-) 
 
The fifth population; Megakaryocyte-Erythroid Progenitor: MEP - CD34+CD38+CD90-
CD123
lo/neg
CD45RA- (Lin-) was not included of practical reasons, the BD FACS Aria are 
able to sort only four populations simultaneously in 5 mL FACS tubes and the sample amount 
was limited. 
 
Compensation controls were performed and includes BD Comp beads Anti-mouse Ig, κ (Cat 
no 552843) single stained with all the surface markers in the panel and a single tube with 
unstained cells, similar to the set up for analysis of intracellular signaling in the five stem and 
progenitor populations. A live/dead marker (Propidium Iodide) in a single tube was included 
in the sort set up in addition to excluding necrotic and apoptotic cells and debris by gating on 
the Forward scatter (Area) versus Side scatter (Area) dot plot. Unstained cells were included 
as negative control. Doublets and other events with unwanted light scatter properties were 
gated out in a forward scatter width versus area plot. Cytometer Setup & Tracking (CST) 
quality control was performed daily before setting up for cell sorting. Prior to sorting the cell 
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suspension was filtered through a 40 m cell strainer (BD Falcon, Becton Dickinson Labware 
Europe, Le Pont de Claix, France). The sorted cells were collected and the cell number was 
marked on the different sterile 5 mL tubes (Becton Dickinson Labware Europe, Le Pont de 
Claix, France) for further experiments. All cell work was carried out under sterile conditions 
except for the sorting. The sorter is not placed in a sterile environment. 
 
The Aria was set up with a 70 m nozzle and 90 Pounds per square inch (psi) pressure that 
makes it possible to run about 10 000-30 000 events per second for rapid enrichment with 
acceptable purity of the sorted populations (result: >95% purity). The air pressure forces the 
sample cells through an optically gel-coupled cuvette flow cell, special designed for the BD 
Aria model that ensures lasers to be precisely focused on the single cells in the sample stream. 
The flow cell optimizes the resolution and sensitivity of the fluorochromes and improves the 
collection efficiency by the no-need for alignment of the lasers on a daily basis or when the 
sorting is interrupted by a clog in the sample unlike the jet-in-air FACS cell sorters. 
 
3.4 In vivo evaluation of human hematopoiesis through xenotransplantation of purified 
hematopoietic stem cells from G-CSF stimulated healthy donor leukapheresis material. 
Stem cell activity was evaluated by the in vivo assay—transplantation of human cells to 
immunodeficient NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF 
and IL-3 (NSGS) mice.  These mutant mice combine the NOD/ShiLtJ background, the 
severe combined immune deficiency mutation (SCID) and IL-2 receptor gamma chain 
deficiency. As a result, the NSGS mice lack mature T cells, B cells, or functional NK cells, 
and are deficient in cytokine signaling and this should lead to better engraftment of human 
hematopoietic stem cells and peripheral-blood mononuclear cells of the myeloid lineage. 
 
The four populations sorted by the FACS cell sorter (HSC, MPP, CMP and GMP) were left 
over night in staining buffer before transplantation. Next morning the different tubes were 
checked for viability on the cell sorter. Cells were spun down and washed once with sterile 9 
mg/mL NaCl (Fresenius Kabi, Germany). The supernatant was removed and 100 L NaCl      
9 mg/mL added to the cells. The cell suspensions were transferred to insulin syringes (U-100 
Insulin 0,5 mL, B.Braun, Germany) on ice and transported to the animal keeping facility, 




The cells from the four different populations were injected through the tail vein and a negative 
(non- injected) mouse was included in the experiment. The mice were treated according to the 
animal facility guidelines, and experiments approved by the national animal ethics committee. 
Stem cell activity was not evaluated from healthy donor bone marrow due to limited material.   
 
Peripheral blood samples were taken from the facial vein with a lancet and a small blood 
collecting tube containing EDTA as anticoagulant every second week from week 6 after 
injection. At week 6 peripheral blood was incubated with anti-human CD45 30 minutes in the 
dark, room temperature. After incubation erythrocytes were lysed with PharmLyse (cat no 
558049, BD Biosciences) in 8 minutes. Cells were then washed twice with PBS and 
resuspended in 250 L PBS. The samples, included the negative control were analyzed using 
the same BD LSR Fortessa as for the signaling experiments. Blood samples were taken every 
second week from week 6 and stained for CD45. 
 
3.5 In vitro evaluation of the four populations, HSC, MPP, CMP and GMP: 
Hematopoietic Colony Forming-Unit (CFU) assay.  
Prospectively FACS sorted cell populations from leukapheresis (HSC, MPP, CMP and GMP) 
were plated in duplicate in 0.4 mL methylcellulose-based H4433 Methocult® medium 
(StemCell Technologies Inc., Vancouver, Canada) in wells on a 24-well plate. Remaining 
wells were filled with 0.4 mL sterile 9 mg/mL NaCl to prevent the Methocult medium from 
drying out and secure optimal humidity during incubation period. Plates were incubated at 
37°C in a humidified incubator at 5% carbon dioxide. After 8 days, the number of colonies 
was examined. After 21 days the number of colonies was counted and images were taken by 
using Zeiss Axio Vert.A1 an inverted microscope with camera. The CFU assay was repeated 
once and this time the colony-forming units (CFUs; CFU-granulocyte and macrophage, burst-
forming units–erythroid, and colony-forming units-mixed) were counted after 10 days using 
the inverted microscope. The four populations were plated in duplicate as the first time.  
 
3.6. Statistical analysis 
Statistical analysis was performed by using the GraphPad PRISM® (version 6.0, GraphPad 







4.1 Establishment of an antibody panel for evaluation of signal transduction in 
hematopoietic stem cells and myeloid progenitors.  
To be able to study human normal bone marrow signal transduction profiles in defined sub- 
populations five well characterized panels of direct conjugated antibodies for  human 
hematopoietic stem cells and myeloid progenitors were established [23]. The five sub 
populations were hematopoietic stem cells (HSCs), multipotent progenitors (MPPs), common 
myeloid progenitors (CMP), granulocyte- macrophage progenitors (GMPs), and 
megakaryocyte- erythroid progenitors (MEPs). The panel of antibodies was adapted for 
analysis on a BD Fortessa flow cytometer.  
4.1.1 Building an antibody panel.  
The specific clones of the antibodies used for this particular protocol with surface markers 
and intracellular signalling antibodies have been described by others [23, 68]. To combine the 
ideal fluorochromes a spectral viewer tool and Brightness Index from BD Biosciences were 
used to determine the best fluorochrome combination. To minimize spectral overlap 
fluorochromes were spread over multiple lasers. The specific fluorochromes were chosen 
according to antigen ranking.  
1: Necessary antigens: Basic phenotypes like Lin-, CD34, CD38, use fluorochromes with spill 
over problems 
2: Important subset antigens like CD45RA, CD123, CD90 with fluorochromes that perform 
well with little bleedthrough problems. 
3: Random antigens, intracellular antigens or dim antigen density like p53, Stat3, Stat5 
require the brightest fluorochromes with the least spill over problems like PE and AF647  
These criteria are important for choosing the optimal fluorochromes for the antibodies in the 
panel but the most significant limitation may be commercial availability of fluorochromes 
conjugated to defined clones. 
4.1.2 Titration of antibodies 
Titration of the antibodies was performed to obtain optimal balance of brightness between the 
fluorochromes. Correct titrated antibodies will also influence on the degree of bleedthrough 
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between emission of the various fluorochromes and not just the intended signal. The sample 
material used for titration was both primary cells like peripheral blood, leukapheresis product 
and cell lines depending on the actual antibodies. For CD34 and CD90 positivity the cell line 
KG1a was used in addition to leukapheresis product. For p53 signal MOLM-13 was used. For 
phospho-Stat 3/5 and Erk1/2 the cell line U937 was used. For all other surface antibodies 
peripheral blood and leukapheresis product were used. The last evaluation was done when the 
antibodies was combined in the panel and tested out on live cells and compared to fixed and 
permeabilized cells. 
4.1.3 Fixation and permeabilization for intracellular antibodies 
Signal intensity is affected not only by titration of antibodies but also by a good fixation and 
permeabilization optimization to ensure accessibility of intracellular antigens and preservation 
of surface markers. The timepoint and concentrations, choice of cytokines and fixation and 
permeabilization agents have already been performed in-house, and it is confirmed by studies 
of Gary Nolan lab at Stanford University, CA, US [69, 70].  
The fixation and permeabilization time was tested on fresh leukapheresis product, 5 x10
6 
/mL.  
5-, 10-, 15- and 30 minutes fixation were tested and surface markers were stained for right 
after fixation.10 min fixation and 30 min permeabilization in the fridge at approx. +4C were 
optimal for the expression of the surface - and intracellular antibodies of this panel.  
4.1.4 Gating controls 
In addition to compensation controls, an unstained control and a Fluorescence Minus One 
(FMO) control for CD38 was included because there was no clear division between positive 
and negative populations [71].  An immunoglobulin isotype control for total p53 protein was 
tested but no difference in level of staining from the unstained sample was observed. The 
isotype control was not included in the protocol for staining. The FMO control identify 
contribution of spillover into one particular detector and facilitate precise gating on 
negative/positive population boundaries, isotype controls can help identify staining issues and 
unstained controls show the background or autofluorescence of the cells used. 
4.1.5. Controls for the signal transduction profile 
Since one of the purposes of this study was to evaluate normal samples and response to 
treatment with cytokines, untreated or unstimulated cells provided the best control for 
evaluating background staining. Unstimulated control cells were included in the protocol and 
were handled identical to the cytokine stimulated cells. This should take into account the 
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unique background characteristics of each antibody as well as the basal phosphoprotein 
expression level. To control the functionality of the cytokines used in the study PBMC and 
three cell lines were used, U937, Molm-13 and KG1a and expected result was achieved. 
 
4.2 Phosphoprotein response to cytokine treatment of subpopulations of CD34 positive 
human hematopoietic cells. 
4.2.1 Comparing signaling patterns of non-stimulated sample from healthy bone 
marrow and G-CSF treated donor leukapheresis product 
A staining protocol for flow cytometry was developed to allow for detection of surface 
marker expression and simultaneous intracellular phosphoprotein detection in five defined sub 
populations.  Flow cytometry was the method of choice because it is ideal for detection of 
signaling response mediated by protein phosphorylation in subsets of complex cell mixtures 
such as bone marrow, cord blood and leukapheresis products. The subsets were: 
hematopoietic stem cells HCS´s, multipotent progenitors MPP´s, common myeloid 
progenitors CMP´s, granulocyte- macrophage progenitors GMP´s and megakaryocyte-
erythroid progenitors MEP´s. 
To evaluate the direct effects of the cytokines, G-CSF and IL-3 on the five sub populations, 
cells were treated with G-CSF or IL-3 separately in 5 or 15 minutes. Cells were then fixed 
with paraformaldehyde to preserve the activation state.  
Flowcytometric analysis of bone marrow and leukapheresis samples revealed a heterogeneous 
response within the different sub populations both to the two different cytokines and the two 









Figure 6. Gating strategy for bone marrow mononuclear cells. 
 
 
                                   
 
Figure 6. BM MNC was analyzed for the expression of lineage markers CD34, CD38, CD90, CD45RA and 
HLA-DR by flow cytometry. The upper dot plot is gated on lineage-negative (Lin-) viable events whereas below 
left dot plot is gated on the CD34 positive CD38 negative events and show the distribution of the HSC and MPP 
populations. The below right dot plot is gated on CD34 positive CD38 positive events and show the distribution 






























Live cell/Lin- gating 
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Figure 7. Flowcytometric analysis of intracellular signal transduction reveals heterogeneity in subpopulations of 

















Figure 7:  
Hematopoietic Stem Cells (HSC) - CD34+CD38-CD90+CD123-CD45RA- (Lin-) 
Multipotent Progenitor (MPP) CD34+CD38-CD90-CD123-CD45RA (Lin-)  
Common Myeloid Progenitor (CMP) CD34+CD38+CD90-CD123+CD45RA- (Lin-)  
Granulocyte-Macrophage Progenitor (GMP) - CD34+CD38+CD90-CD123+ CD45RA+ (Lin-)  
Megakaryocyte-Erythroid Progenitor (MEP) - CD34+CD38+CD90-CD123lo/neg CD45RA- (Lin-)  
 
Mean fluorescence intensity was calculated and compared to untreated controls. Results are displayed as bar 
graphs of the mean ± SD of five separate bone marrow donors.  Graphs show results both for 5 and 15 minutes 










Figure 8. Bone marrow mononuclear cells, represented by donor 4. Heatmap of the transformed medians by first 
row of cells responding in each stem and progenitor sub population. The heatmaps present the variations in the 
data files via variations in color. 
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Figure 9. Allogeneic leukapheresis product (LP) – 2 donors.  Heatmap of the transformed medians by first 
row of cells responding in each stem and progenitor sub population presented for LP Donor 1:  
5 min   HSC    MPP    CMP 
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LP Donor 2: 
5 min  HSC    MPP    CMP 
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 GMP    MEP 
 
 
All in all the heatmaps of the two leukapheresis products demonstrates a characteristic lower 
response to the cytokines G-CSF and IL- 3 than the bone marrow samples. However, in the 15 
minutes samples we observe an inhibited response for Stat3 with IL-3 stimuli opposite to 
Stat5(tyr694) and IL-3 were we could observe an increased response after 15 minutes in the 
GMP and MEP populations than for the other three less differentiated populations. The 






4.2.2 Signaling patterns for Stat3 of unstimulated sample from bone marrow and 
leukapheresis product. 
The Stat3(tyr705) histogram of the non-stimulated sample from the leukapheresis product 
revealed a bimodal peak we could not observe for the non-stimulated bone marrow samples 
for the different sub populations. This is likely because the cells have a much higher basal 
phosphorylation level compared to the bone marrow cells. Taken together it is possible that 
these results demonstrate that G-CSF stimulated sub populations represent biochemically 
distinct subsets. Bimodal peaks can indicate that a particular population contains sub-
populations of cells that need to be identified with more surface markers. Furthermore it is an 
indication of an already phosphorylated state due to the G-CSF treatment of the donors. 
Figure10. Comparison of normal bone marrow phospho-signaling profile for Stat3(tyr705) and allogeneic 
leukapheresis product. 
 
Figure10. The figure demonstrates the bimodal peak in MPP, CMP and GMP compartment in the unstimulated 
sample of the allogeneic LP product. In the HSC and MEP compartment it is not observed a bimodal peak. Bone 




4.3 Evaluation of the antibody panel for surface markers evaluated both in vivo and in 
vitro. 
 
4.3.1 Flow Cytometry Activated Cell sorting (FACS) 
To be able to evaluate the functionality of the different stem- and progenitor popluations and 
the gating strategy in the flow cytometry analysis part, a Flow Cytometry Activated Cell 
Sorting (FACS) protocol was established. The gating strategy for the surface markers were 
approximately the same as for the intracellular phospho-flow protocol as demonstrated in 
figure 7a. A postsort analysis was performed on the sorted populations as shown in figure 7a. 
To be able to keep the cells alive it was not possible to include the intracellular antibodies. 
Validation of signaling in sorted populations was not performed, but should be considered for 
future experiments to internally confirm signaling responses in the defined cell populations.  
Figure 11a.  FACS viable cell sorting of HSC, MPP, CMP and GMP sub populations of CD34 positive cells, 50 
000 events were recorded while sorting.    
 
 








Figure 11b show that the sample can be stored over-night in a cold room at approximately +6C before sorting. 
Both the viability and the antibody pattern remain unchanged from the day before. 
 
Next day viability check on the sorted populations after 11 hours in cooling room showed the 
same result as the day before, viability (according to light scatter plot) at 96 % and the 
population was falling into the same purity gate. Figure not shown. 
 
4.3.2 In vitro evaluation of sub populations of CD34+ hematopoietic cells. 
Colony Forming Unit (CFU) assay was performed twice with FACS sorted sub populations 
(HSC, MPP, CMP, GMP) in duplicates in a 24 well plate. The first time the colonies were 
characterized and photographed but not classified as colonies, see figure 8. The HSC growth 
pattern showed small dense white colonies, some larger single white cells and some red small 
Post sort analysis of 
HSC, MPP, CMP 
and GMP  
Figure 11b: Analysis of rest-




colonies, 46 colonies in total. MPP colonies were characterized by both small colonies and 
small and large cells in colonies together, and some small red cell colonies, 47 in total.  CMP 
had both small and large cells in colonies and some colonies with only big white cells and few 
red cell colonies, 35 in total. GMP had 7 colonies in total, large cells in colonies with small 
cells among them. The second time the different colonies were counted after 14 days for each 
sub population. Colony counting doublet average:  
Table 3. 
 CFU-G CFU-M CFU-GM BFU-E 
HSC 21 27 36 38 
MPP 78 58 34 56 
CMP >100 39 >100 >100 
GMP 8 22 25 9 
 
Cultured cells were:  50 000 (HSC), 30 000 (MPP), 30 000 (CMP) and 10 000 (GMP)  
 










HSC, 5x objective 
CFU-GM and BFU-E 
MPP, 5x objective 
BFU-E 






4.3.3 Engraftment and localization of human hematopoiesis of NSGS mice after 
transplantation of human sub populations of CD34+ cells. 
Sorted HSC, MPP, CMP and MEP subpopulation from two donors were injected into 
NSGS[72] mice for detection of human repopulating cell activity. The results obtained so far 
by flow cytometry for human CD45 and CD33 show no positive events. Leukapheresis 
products have been FACS sorted and the four sub populations HSC, MPP, CMP and GMP 
have been transplanted twice. A not transplanted NSGS mouse is kept as a negative control.  
Samples from peripheral blood from both the transplanted animals and the negative control 
mouse have been analyzed every second week since week six after transplantation and it will 
continue until week 20 were the mice will be sacrificed and samples taken for flow cytometry 
analysis from bone marrow, spleen and peripheral blood to assess long term human 
engraftment. 
 
Figure 13a.  Flowcytometric analysis of NSGS mice peripheral blood stained with human CD45 and human 
CD33 to detect leukocytes and cells from the myeloid compartment. Group 1 (HSC, CMP, GMP) analyzed 10 
weeks after transplantation. MPP-mouse was sacrificed after four weeks due to an unspecified tumor in relation 
to the scapular bone.  
 
     
 
Figure 13b. Flowcytometric analysis of NSGS mice peripheral blood stained with human CD45 and human 
CD33 to detect leukocytes and cells from the myeloid compartment. Group 2 analyzed 6 weeks after 
transplantation.  
    
 
In neither groups there are significant human CD45 positive events at 6 weeks and the study 





This thesis contains of three parts.  The first part describe establishment of a robust 
antibody panel and protocol for staining of hematopoietic stem- and progenitor cells to 
study intracellular signal transduction. The material examined was bone marrow 
donated from healthy individuals, leukapheresis product from healthy donors for 
allogeneic bone marrow transplantation. A separate protocol for cord blood has not 
been done due to logistics problems. Five subpopulations of CD34+ cells from healthy 
individuals have been defined by a set of antibodies (Lin-, PARP, CD34, CD38, CD90, 
CD45RA,CD123) and examined for the phosphorylation level in Stat3(tyr705), 
Stat5(tyr694), Erk 1/2. In addition the total level of the cell stress sensor and tumor 
suppressor protein p53 was examined. In the second part a FACS sorting protocol using 
the same surface markers was established for leukapheresis product with the purpose of 
isolating the different subpopulations. In the third part, cells from the sorted and 
isolated cells from part two were evaluated for protocol and the gating strategy using 
the Colony Forming Unit ex vivo method, and also xenotransplanted into NSGS mice. 
 
Multicolour flow cytometry is the main technique employed for analysis of intracellular 
signalling in this thesis. Other methods to study signalling proteins include gene 
sequencing, immunohistochemistry, mass spectrometry, western blot and micro array 
analysis. The advantage of measuring protein levels and level of protein modification by 
flow cytometry is the ability to determine heterogeneity within specific subpopulations 
of cells. Possible limitations and weaknesses of flow cytometry will be discussed. 
 
5.1  Establishment of antibody panel and protocol for staining 
 
5.1.1.   Sample handling and preparation 
Proper sample handling is essential to avoid induction of artefacts. Bone marrow 
samples from healthy individuals have been frozen for different periods of time and 
some of samples were leftover product after removing of B-cells. Since the bone marrow 
samples are limited material it was not possible to control the sampling, storage or 
freezing procedures. Handling procedures may affect the final results regarding antigen 
preservation, cell viability and activation status. Given that  total p53 is increased in cells 
exposed to diverse stress signals like DNA damage, ribosomal stress and hypoxia [73] it 
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was not expected to observe any increase in p53 signal for the healthy bone marrow and 
allogeneic leukapheresis products. However, we find a slight p53 increase both for 
untreated cells and stimulated cells in the bone marrow samples in figure 7. The 
response of total p53 for the bone marrow samples are more consistent compared to the 
leukapheresis products. This may indicate that the quality of fresh samples handled 
within two hours after end of collection is more ideal for signalling studies than frozen 
material. These data propose that total p53 can be used as an indicator of sample quality 
combined with a marker for cell death and/or apoptosis and a gating strategy that 
include exclusion of debris and non-typical events in a light scatter plot. 
 
5.1.2 Antibodies, cytokine concentrations and time points 
Antibodies recognize antigenic determinants, also called epitopes on their antigen. The 
specificity to epitopes and sensitivity of antibodies varies a lot from clone to clone. In 
this thesis the antibodies of choice are parts of an established panel used in several 
papers.[23, 74] The panel in this study is built after a model from Gibbs paper and all 
potential antibodies against each epitope are not tested. The results from the 
establishment of the panel showed that the CD90 (5E10) expression was highly 
increased after permeabilization when the surface staining was done together with the 
intracellular staining. As a consequence CD90 staining was done before 
permeabilization. Another fluorochrome with the same antibody clone was tested with 
the same result. No further investigation was done to examine the phenomenon. Also to 
assess four signaling proteins (total p53, phosphorylation of Stat3, Stat5, and Erk1/2) in 
one panel with the choice of fluorochromes in the thesis without decreasing the 
sensitivity of the antibodies was not possible and the conclusion was to use two panels, 
one for Stat3 and Stat5 and one for p53 and Erk1/2 with the identical surfacemarker 
antibodies for both tubes.  
 
The concentration of cytokines in the thesis is also chosen on the basis of the paper by 
Gibbs et al and the time points were chosen according to earlier work done by the 
Gjertsen lab [75]. To be able to determine the optimal concentration of the cytokines and 
time points for detection of optimal phospho-signalling, a concentration titration and a 





5.1.3   Controls 
Controls included in the study are quality controls for the flow cytometer (CS&T), 
unstained control, compensation controls, gating controls/biological controls. A 
matched isotype control for p53 antibody was tested but no unspecific staining was 
found due to the isotype control. The isotype control and the unstained control had 
identical levels. The conclusion was not to include the isotype control in the panel.  
Isotype controls are meant to account for unspesific staining but not for fluorochrome 
spillover. There are two important considerations to take into account with using 
isotype controls. The first limitation is that individual antibody conjugates have various 
levels of background staining, depending on specificity, concentration and 
fluorochrome:antibody ratio (F/P ratio) among other variables. The second limitation is 
that it does not account for fluorochrome spillover from other detectors. This can be 
overcome by including all relevant antibodies in the panel along with the isotype control 
in the detector of interest and you will have a Fluorescence Minus One (FMO) control.   
 
For the surface marker CD38 in the panel where there is no clear division between 
positive and negative populations a gating control (FMO) was included. The gating 
control can be a biological comparison control (unstimulated or irrelevantly stimulated 
cells) or an isotype control/FMO control. For the signalling antibodies the unstimulated 
samples provided the best control to distinguish positive events from negative events  
[71].   
 
5.2 Signal transduction assay 
Part of the objective of this thesis was to develop a robust protocol to detect activated 
signalling pathways within the five defined subpopulations of CD34+ cells in the samples 
by simultaneously staining for surface markers and intracellular phosphorylated 
proteins for flow cytometry. By using a flow cytometric strategy fewer cells are required 
when compared to alternative techniques including western blotting. Western blotting 
and flow cytometry has previously been compared and provide similar qualitative 
results for phosphorylated protein analysis [70] 
Flow cytometry however allows one to identify individual cells with different 
responsiveness, rather than a mean value for the total cell population without 
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separating cells prior to stimulation and analysis. For the five subpopulations 
investigated in this thesis it is in practice impossible to use western blot because of the 
small amounts of cells located in each sub population.  
 
5.2.1 Permeabilization step is critical for the surface epitopes 
Several protocols for detection of intracellular/nuclear epitopes is described [69, 70] 
and fixation and permeabilization steps are widely discussed. In this study 
permeabilization conditions were tested for concentration of methanol and incubation 
temperature. The permeabilization step is crucial to allow passage of the intracellular 
antibodies without destroying the structural integrity of the cells. Based on this both 
90% methanol and 70% methanol was tested in combination with incubation 
temperature ranging from minus 20°C, on ice until or up to +4°C in the fridge. Incubation 
time was also tested, 10 minutes, 15 minutes and 30 minutes. We observed a decrease in 
the intensity of CD38 signal and a total positive signal of CD90 when 90% methanol was 
used and the cells were kept on ice or in -20. The phosphorylated epitopes was still 
intact when cells were exposed to 70% methanol for 30 minutes in the fridge and the 
cell surface labelling was sufficient. 
 
5.2.2   Comparison of signalling patterns from bone marrow and leukapheresis 
product 
Based on the observations of the signalling patterns after cytokine exposure the most 
interesting findings for us were a significant difference in the signalling pattern between 
specimens. While conclusions from studies using model systems have described the HSC 
sub population only responding to a set of early acting cytokines such as SCF and TPO 
[76, 77]. This study demonstrates a heterogeneous and substantial response for the two 
timepoints to single stimuli based on the mean fluorescence intensity ratio on 
unstimulated samples compared to stimulated samples and the results are confirmed by 
the study of Gibbs et al[23]. It was not possible in this study to observe the decreasing 
response from G-CSF in the more mature progenitor populations.  On the other hand we 
observed a similar response to IL 3 from the Stat3(tyr705) and Stat5(tyr694) antibody. 
The bone marrow samples have an increased response from Stat5 from all the five sub 
populations as for the study done by Gibbs et al. An important observation from the two 
leukapheresis samples is a negative expression for the 15 minutes activation samples. 
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This is a very interesting observation and to further investigate this more donors are 
needed to make the statistics more robust. In addition confirmation of the result from 
other methods like proliferation in direct response to G-CSF and/or IL-3, receptor status 
with antibody staining for G-CSF receptor (CD114) and IL-3 receptor (CD123). CD123 is 
actually included in this study as a marker for progenitors. To conclude on the different 
responses from the frozen bone marrow samples from five donors and fresh 
leukapheresis products from two donors the most central observations for this study 
are the importance of viability of samples and that optimal time of stimulation vary 
between cytokines. This demonstrates that the context in which responses are 
measured could have a considerable influence on the signals observed.  
 
In the leukapheresis products, our findings of a bimodal peak in the unstimulated 
sample and an approximately identical pattern in the G-CSF stimulated samples are very 
interesting, figure 10. Different Stat3 phosphorylation levels were demonstrated for the 
five different populations. These patterns were only found in the leukapheresis product, 
and not present in the bone marrow samples. The donors were treated with G-CSF 
before the collection of leukapheresis product and it is likely that our signalling analysis 
is reflecting this stimulation in vivo.  The 1.5 hour resting period before activation with 
cytokines seems not enough to reset the cells to zero activation. This observation should 
be further investigated. 
In summary, we provide a protocol that allows successful discrimination of several 
CD34+ sub populations in bone marrow and leukapheresis products. This permits 
detection of intracellular signal transduction. 
It should be reminded that the aim of this study was not to determine differences of 
signal transduction within cell subpopulations among healthy donors. In fact, the goal 
was to assess whether the established protocol can be used as a tool to study expression 
of signal transduction in different material like bone marrow, leukapheresis products 
and cord blood. The study does not fulfill the aim of establish the protocol for cord blood 







5.3 Evaluation of the sub populations by colony forming unit assay.  
FACS sorting of four out of five sub populations (HSC, MPP, CMP and GMP) was done 
prior to the experiments and a control of the purity of the four different populations. 
 
Colony forming unit assay were used to confirm the ability for the four populations to form 
colonies. After adjusting the amount of cells needed performing this assay, the results 
showed an increased amount of colonies in each sub population. The medium used; 
MethoCult cat. No. 4433 is not the commonly used for this type of set up, but according to 
the manufacturer it will give the same result as the cat. No. 4434 Classic. The medium used 
contained phytohemagglutinin leukocyte conditioned medium (PHA-LCM) as a source of 
colony-stimulating factors, plus recombinant human erythropoietin (EPO). The findings 
suggest that the antibodies used and the gating strategies when the cells were sorted are 
well defined. Furthermore, the colonies performed from the four populations showed a 
difference in morphology that further indicate different proliferation and/or differentiation 
steps for the sub populations represent are expressed through the result of the assay. 
 
5.4 Evaluation of the sub populations by xenotransplantation with NSGS mice. 
The NSGS mice strain is developed by cross breeding the NSG strain with the NSS (NS 
mice transgenic for the human cytokines SCF, GM-CSF and IL-3) strain [72]. This strain 
promotes increased human myelopoiesis compared to the NSG mouse. The NSGS strain 
have not previously been used in-house for xenografts with healthy hematopoietic stem 
and progenitor cells so it is difficult to estimate the time point for when to expect the 
transplanted human cells to proliferate and differentiate to a measureable level in 
peripheral blood. It has been reported engraftment after 6 weeks from patient cells 
affected with Myelodysplastic syndrome [78]. However, we have not yet observed any 
positive events in the mice PB samples but the experiment are still going and samples 
are taken every two weeks and stained for human CD45 and human CD33. The project 
will continue until week 20 after xenograft, then the animals will be sacrificed and 
samples taken for flow cytometry analysis from bone marrow, spleen and peripheral 
blood to assess long term human engraftment. In theory this model should be ideal for 
this study. However, it can be discussed if this is a good model for evaluating the 
different sub-populations as long as we have not seen any reports on effect of healthy 
hematopoietic stem- and progenitor cell xenografts with this mouse strain. On the other 
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hand, it is a very interesting experiment if we will be able to detect human blood cells for 
future projects.  
 
The work done here provides a small glimpse into the complex network of signalling 
pathways that regulate growth, differentiation and function of human hematopoietic 
cells. Despite the enormous amount of information that is reported in recent years 
regarding signalling networks many challenges remain. Among others to understand 
how multiple signalling networks act together to create a given biological fate.  
 
5.5. Future perspectives  
Obtained results in this thesis certainly provide an important tool for further studies of 
signalling pathways of human hematopoietic stem- and progenitor cells. Xenograft 
assays are still going and another project are using the antibody panel for studying 
xenografts with patient material from an acute myeloid leukemia. To further refine the 
antibody panel the goal is to combine all four signalling markers in one panel. This will 
be a benefit considering the great cell loss due to the washing steps in the protocol. The 
continuous project will also include cord blood.  So the next step is to establish a 
protocol also for this type of material. Furthermore, it will be interesting to compare 
frozen and fresh material and study the signalling effects. To study the interesting 
findings of the bimodal peaks in the unstimulated samples of the leukapheresis products 
we need to study more samples and evaluate the surface markers.  
It will be of interest to establish an antibody panel were the aim is to study cytokine 
receptor levels, in particular sort cells based on different expression of the G-CSF 
receptor (CD114). By repeating the xenograft experiment with sub populations with 
high and low expression of G-CSF receptors we may validate the study of Gibbs and co-
workers [23] were they found that long term human HSC activity is enriched in the G 
CSF neg/low population. For the ongoing project it is also to interesting to include fresh 
samples of autologous leukapheresis donors and compare the results to the allogeneic 
donors.  
Protein phosphorylation is one of the most biologically significant post translational 
modifications in cells, and requires sophisticated methods for detection. The application 
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of genomic tools like quantitative mass spectrometry (SILAC) to study post-
transcriptional protein modification may be an important supplement in studying 
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